[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625503":3},{"organization":4,"outcomesModule":7,"designInfo":20,"detailedDescription":11,"studyPopulation":23,"armGroups":24,"interventions":30,"overallOfficials":35,"centralContacts":39,"locations":44,"responsibleParty":59,"collaborators":61,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":67,"sex":73,"minAge":74,"maxAge":11,"enrollmentInfo":75,"targetDuration":11,"studyType":78,"phases":11,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":88,"whyStopped":11,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Nantes University Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Describe weight changes during the follow-up period according to patient characteristics.",null,"Baseline",[14,16,18],{"measure":15,"description":11,"timeFrame":12},"Identify the characteristics of patients who continue treatment or switch to other obesity management strategies and the associated factors.",{"measure":17,"description":11,"timeFrame":12},"Compare the profiles of responders and non-responders",{"measure":19,"description":11,"timeFrame":12},"Describe weight change according to different subpopulations.",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":21,"timePerspective":22,"maskingInfo":11},"COHORT","PROSPECTIVE","Patients treated with WEGOVY® (semaglutide 2.4 mg) under temporary authorization for use (ATU) and the early access program in France.",[25],{"label":26,"type":11,"description":27,"interventionNames":28},"SEMAFOLLOW study population","Patient agreeing to participate in the SEMAFOLLOW study.",[29],"Other: SEMAFOLLOW questionnaire",[31],{"type":6,"name":32,"description":33,"armGroupLabels":34,"otherNames":11},"SEMAFOLLOW questionnaire","If the patient agrees, the center will send a link to the questionnaires via email. Patients who have completed the questionnaires will be analyzed in the SEMAFOLLOW study. Estimated time to complete the questionnaire: approximately 30 minutes",[26],[36],{"name":37,"affiliation":5,"role":38},"David JACOBI","STUDY_DIRECTOR",[40],{"name":37,"role":41,"phone":42,"phoneExt":11,"email":43},"CONTACT","+332 53 48 28 35","David.Jacobi@univ-nantes.fr",[45],{"facility":46,"status":11,"city":47,"state":11,"zip":11,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Nantes university hospital","Nantes","France","FR",{"type":51,"coordinates":52},"Point",[53,54],-1.55336,47.21725,{"lat":54,"lon":53},[57],{"name":37,"role":41,"phone":58,"phoneExt":11,"email":43},"+33253482709",{"type":60,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[62],{"name":63,"class":64},"Novo Nordisk A\u002FS","INDUSTRY","100625503","weight-trajectories-and-predictive-factors-after-semaglutide-in-patients-with-grade-3-and-complicated-obesity-100625503",false,"NCT07423481","Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity","SEMAFOLLOW - Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity: Observational, National Cohort, Real-world Study in France","SEMAFOLLOW","Inclusion Criteria:\n\n* Patients included in the ATU\u002Fearly access program for WEGOVY with at least two dispenses of WEGOVY\n* No objection to the use of their data\n* Patients able to complete an online questionnaire (via the internet)\n\nExclusion Criteria:\n\n• Protected patients: minors, adults under guardianship, conservatorship, and\u002For legal protection","ALL","18 Years",{"count":76,"type":77},3000,"ESTIMATED","OBSERVATIONAL","SEMAFOLLOW is a real-world follow-up study examining the outcomes of individuals treated with WEGOVY® (semaglutide 2.4 mg) under the temporary authorisation for use (ATU) and early access programme in France. This study evaluates weight change, treatment strategies and well-being, drawing on the expertise of teams from various specialist obesity centres in France.",[81],"Obesity & Overweight",[83,84,85,86,87],"WEGOVY®","sémaglutide 2,4 mg","Obesity","Overweight","ATU","NOT_YET_RECRUITING","2026-09-15",{"date":91,"type":92},"2026-09-18","ACTUAL",{"date":94,"type":77},"2026-10-01",{"date":96,"type":77},"2027-07-01",{"name":5,"class":6},1]